Therefore, it is important to determine the relative expression and cellular location of HER2 in a larger group of GBM patients and its potential as a therapeutic target, prognostic marker, and predictive indicator for the response to therapy with the EGFR and HER inhibitors. This evidence concerns the gene EGFR and glioblastoma.